Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Graft-versus-host disease (GVHD) is a serious condition that can happen after a stem cell transplant from a donor. The donated cells see the healthy tissues in the recipient's body as foreign and attack them. TRX103 is a new drug designed to reduce the risk of GVHD.
The purpose of this study is to assess the safety and effectiveness of combining a "bivalent" vaccine with two agents that stimulate the immune system: a sugar called beta-glucan and a medication called GM-CSF. The treatment is designed to prevent the relapse of patients with high-risk neuroblastoma that is in complete remission. This bivalent vaccine works by stimulating an immune response against two different antigens, which are markers on the surface of a cell.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
Researchers are comparing standard bladder cancer treatment with TAR-210. The people in this study have bladder cancer that has not grown into the muscle wall. Their cancer has a mutation (change) in the FGFR gene.
Cancer that has spread from a solid tumor to the membranes lining the brain and spinal cord (leptomeninges) is called "leptomeningeal metastasis." Cerebrospinal fluid (CSF) is located between the leptomeninges, in a place called the "intrathecal space." Cancer cells within the CSF rely on iron for growth and survival. Researchers think that the study drug, deferoxamine (DFO), may be an effective treatment for leptomeningeal metastases because it helps remove iron from the body (including the CSF).
Chemotherapy for lymphoma can cause side effects, especially in people age 65 and older and those with other health problems. Researchers want to see if adding the immunotherapy drugs glofitamab, polatuzumab, and obinutuzumab to treatment can reduce the amount of chemotherapy needed. The people in this study have diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma (HGBCL), or transformed lymphoma. Their cancer has not yet been treated.
The purpose of this study is to assess the safety and effectiveness of combining pembrolizumab immunotherapy with standard chemotherapy drugs and autologous stem cell transplantation (ASCT) in patients with Hodgkin lymphoma that has come back or continued to grow despite one regimen of prior therapy. Pembrolizumab blocks PD-1, a protein cancer cells use to evade detection by the immune system, thereby enabling the immune system to find and kill cancer cells.
Teclistamab is given as an injection under the skin. The goal is to see if lower doses or stopping treatment will have the same benefit with fewer side effects.
Researchers are doing this study to see if the combination of epcoritamab, zanubrutinib, and rituximab works well against lymphoma. The people in this study have follicular lymphoma that has come back or keeps growing after treatment.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
